{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:58:24Z","timestamp":1782446304175,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","pediatric.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.pcl.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T03:22:41Z","timestamp":1417144961000},"page":"107-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Chronic Myeloid Leukemia in Children"],"prefix":"10.1016","volume":"62","author":[{"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Millot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2014.09.008_bib1","unstructured":"Surveillance Research Program NCI. Fast Stats: An interactive tool for access to SEER cancer statistics. 2013. Available at: http:\/\/seer.cancer.gov\/faststats\/. Accessed November 1, 2013."},{"key":"10.1016\/j.pcl.2014.09.008_bib2","series-title":"Cancer incidence and survival among children and adolescents: United States SEER Program 1975\u20131995","year":"1999"},{"key":"10.1016\/j.pcl.2014.09.008_bib3","unstructured":"Childhood acute myeloid leukemia\/other myeloid malignancies treatment (PDQ\u00ae). 2014. Available at: http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/childAML\/HealthProfessional\/page1#Reference1.3. Accessed June 22, 2014."},{"issue":"14","key":"10.1016\/j.pcl.2014.09.008_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"10.1016\/j.pcl.2014.09.008_bib6","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.008_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.008_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib9","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"s1","key":"10.1016\/j.pcl.2014.09.008_bib10","first-page":"238","article-title":"The EUTOS population-based registry; evaluation of baseline characteristics and first treatment choices of 2983 newly diagnosed chronic myeloid leukemia (CML) patients from 20 European countries","volume":"99","author":"Lindoerfer","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pcl.2014.09.008_bib11","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood.V120.21.3741.3741","article-title":"The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and preliminary results","volume":"120","author":"Millot","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV","volume":"93","author":"Kalmanti","year":"2013","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.pcl.2014.09.008_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2014.09.008_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation","volume":"2010","author":"Suttorp","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","article-title":"Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study","volume":"95","author":"Mitra","year":"2012","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.008_bib18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/gcc.21989","article-title":"Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia","volume":"51","author":"Krumbholz","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pcl.2014.09.008_bib19","unstructured":"Network NCC. NCCN Clinical practice guidelines in oncology; chronic myelogenous leukemia. Version 1.2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#cml. 2013. Accessed October 19, 2014."},{"issue":"6","key":"10.1016\/j.pcl.2014.09.008_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.pcl.2014.09.008_bib23","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood.V122.21.2725.2725","article-title":"Scoring systems for predicting outcome of chronic myeloid leukemia in adults are poorly informative in pediatric patients treated with imatinib","volume":"122","author":"Suttorp","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.008_bib24","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation","volume":"66","author":"Sokal","year":"1985","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and\u00a0>10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12892","article-title":"How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia","volume":"166","author":"Ross","year":"2014","journal-title":"Br J Haematol"},{"issue":"Suppl 10","key":"10.1016\/j.pcl.2014.09.008_bib29","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1002\/1097-0142(19930515)71:10+<3206::AID-CNCR2820711706>3.0.CO;2-A","article-title":"Cancer in adolescents and young adults","volume":"71","author":"Reaman","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.008_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.pcl.2014.09.008_bib32","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2014.09.008_bib34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V120.21.916.916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts","volume":"120","author":"Rea","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.008_bib35","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/pbc.25090","article-title":"Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia","volume":"61","author":"Moser","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib","volume":"92","author":"La Rosee","year":"2013","journal-title":"Ann Hematol"},{"issue":"26","key":"10.1016\/j.pcl.2014.09.008_bib38","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.pcl.2014.09.008_bib40","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia","volume":"122","author":"Warsch","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11899-012-0148-8","article-title":"Targeting chronic myeloid leukemia stem cells","volume":"8","author":"Kinstrie","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrclinonc.2010.141","article-title":"Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination","volume":"7","author":"Bocchia","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.pcl.2014.09.008_bib43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00262-011-1126-z","article-title":"Antigens in chronic myeloid leukemia: implications for vaccine development","volume":"60","author":"Smahel","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.008_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","article-title":"Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: The Japan Marrow Donor Program","volume":"16","author":"Muramatsu","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.008_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib46","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.008_bib47","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.pcl.2014.09.008_bib48","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.008_bib49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","article-title":"Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy","volume":"26","author":"Shami","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib50","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pcl.2014.09.008_bib51","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.pcl.2014.09.008_bib54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"issue":"9633","key":"10.1016\/j.pcl.2014.09.008_bib55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.008_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.pcl.2014.09.008_bib57","first-page":"1049","article-title":"Survival after hematopoietic stem cell transplantation (HSCT) or tyrosine kinase inhibitors (TKI) in children with chronic myeloid leukemia (CML) in chronic phase; a single institution experience. May 9\u201312","volume":"58","author":"Hijiya","year":"2012","journal-title":"Ped Blood Cancer"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib59","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.pcl.2014.09.008_bib60","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1182\/blood.V120.21.3752.3752","article-title":"Impact of treatment with tyrosine kinase inhibitors (TKIs) on blood levels of growth hormone-related parameters, testosterone, and inhibin B in juvenile rats and pediatric patients with chronic myeloid leukemia (CML)","volume":"120","author":"Ulmer","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pcl.2014.09.008_bib61","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pcl.2014.09.008_bib62","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","article-title":"A\u00a0dramatic fetal outcome following transplacental transfer of dasatinib","volume":"23","author":"Berveiller","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beha.2009.09.008","article-title":"CML in pregnancy and childhood","volume":"22","author":"Apperley","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.008_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2011.09.025","article-title":"Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model","volume":"36","author":"Schultheis","year":"2012","journal-title":"Leuk Res"},{"issue":"20","key":"10.1016\/j.pcl.2014.09.008_bib65","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib66","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.008_bib67","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.008_bib68","first-page":"723","article-title":"Thyroid dysfunctions induced by tyrosine kinase inhibitors","volume":"13","author":"Fallahi","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.pcl.2014.09.008_bib69","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.leukres.2011.01.021","article-title":"Nilotinib cardiac toxicity: should we still be concerned?","volume":"35","author":"Atallah","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.008_bib70","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.008_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.pcl.2014.09.008_bib72","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pcl.2014.09.008_bib73","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.008_bib74","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib75","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.pcl.2014.09.008_bib76","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.pcl.2014.09.008_bib77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","article-title":"Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium","volume":"29","author":"Aplenc","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.pcl.2014.09.008_bib78","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.pcl.2014.09.008_bib79","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pcl.2014.09.008_bib80","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.pcl.2014.09.008_bib81","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pcl.2014.09.008_bib82","unstructured":"Larson RA, Saglio G, Kim DW, et\u00a0al. Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update. Paper presented at: American Society of Clinical Oncology (ASCO) Annual '13 meeting. Chicago, 2013. J Clin Oncol 2013;31 (suppl; abstr 7052)."},{"issue":"5","key":"10.1016\/j.pcl.2014.09.008_bib83","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.008_bib84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.008_bib85","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host","volume":"96","author":"de Lavallade","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.008_bib86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1745-7599.2006.00163.x","article-title":"Safety of live-virus vaccines for children with immune deficiency","volume":"18","author":"Luthy","year":"2006","journal-title":"J\u00a0Am Acad Nurse Pract"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395514001874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395514001874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T08:31:41Z","timestamp":1598517101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395514001874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0031395514001874"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2014.09.008","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myeloid Leukemia in Children","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}